Severe laryngeal dystonia in a patient receiving zuclopenthixol 'Acuphase' and fluoxetine

Australasian Psychiatry

Volumn 18, Issue 2, 2010, Pages 174-176

  Hood, Sean ^a   Orr, Kenneth ^b   Bennett, Lynette ^b   Davies, Simon ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b RANZCP (Western Australia Branch)   (Australia)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Acuphase; Dystonia; Fluoxetine; Interaction; P450; Zuclopenthixol

Indexed keywords

ACUPHASE; BENZATROPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUOXETINE; NITRAZEPAM; QUETIAPINE; UNCLASSIFIED DRUG; ZUCLOPENTHIXOL ACETATE;

ADULT; ARTICLE; BORDERLINE STATE; CASE REPORT; CONSULTATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG OVERDOSE; DYSPNEA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INTRAVENOUS ADMINISTRATION; LIAISON PSYCHIATRY; MAJOR DEPRESSION; MORNING DOSAGE; OXYGEN THERAPY; PSYCHOTHERAPY; SPASMODIC DYSPHONIA; STRIDOR;

ADULT; ANTIPSYCHOTIC AGENTS; CLOPENTHIXOL; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSTONIA; FEMALE; FLUOXETINE; HUMANS; LARYNGEAL MUSCLES; SEROTONIN UPTAKE INHIBITORS;

EID: 77949907656     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.3109/10398560903473686     Document Type: Article

References (13)

1. Horgan D, Dodd S, Berk M. A survey of combination antidepressant use in Australia. Australasian Psychiatry 2007; 15: 26-29.
2. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines, 9th Edition. London: Informa HealthCare, 2007.
3. Barnes CW, Alderton D, Castle D. The development of Clinical Guidelines for the use of Zuclopenthixol Acetate. Australasian Psychiatry 2002; 10: 54-58.
4. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Therapeutic Drug Monitoring 2000; 22: 118-121.
5. Jerling M, Dahl ML, berg-Wistedt A et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clinical Pharmacology and Therapeutics 1996; 59: 423-428.
6. Dahl ML, Ekqvist B, Widen J, Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatrica Scandinavica 1991; 84: 99-102.
7. Jaanson P, Marandi T, Kiivet RA et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berlin) 2002; 162: 67-73.
8. Besag FM, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Safety 2006; 29: 95-118.
9. Preskorn SH, Shah R, Neff M, Golbeck AL, Choi J. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. Journal of Psychiatric Practice 2007; 13: 5-12.
10. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry 1996; 153: 311-320.
11. Davies SJC, Westin AA, Castberg I, Lewis G, Lennard MS, Spigset O. Zuclopenthixol interactions with paroxetine, fl uoxetine, carbamazepine and levomepromazine: data from a routine therapeutic drug monitoring service. Journal of Psychopharmacology 2008; 22: A46.
12. Gonzalez FJ, Skoda RC, Kimura S et al. Characterization of the common genetic defect in humans defi cient in debrisoquine metabolism. Nature 1988; 331: 442-446.
13. Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clinical Pharmacokinetics 2002; 41: 453-470